The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity by Cochran, Blake J et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, 
inhibition and clearance of cell surface uPA activity
Blake J Cochran1, Lakshitha P Gunawardhana1,2, Kara L Vine1, Jodi A Lee1, 
Sergei Lobov1 and Marie Ranson*1
Address: 1School of Biological Sciences, University of Wollongong, NSW, 2522, Australia  and 2Current address: Department of Respiratory and 
Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW, 2310, Australia
Email: Blake J Cochran - blake@uow.edu.au; Lakshitha P Gunawardhana - lapg@gmail.com; Kara L Vine - kara@uow.edu.au; 
Jodi A Lee - jal31@uow.edu.au; Sergei Lobov - sergei@uow.edu.au; Marie Ranson* - mranson@uow.edu.au
* Corresponding author    
Abstract
Background: Plasminogen activator inhibitor type-2 (PAI-2, SERPINB2) is an irreversible, specific
inhibitor of the urokinase plasminogen activator (uPA). Since overexpression of uPA at the surface
of cancer cells is linked to malignancy, targeting of uPA by exogenous recombinant PAI-2 has been
proposed as the basis of potential cancer therapies. To this end, reproducible yields of high purity
protein that maintains this targeting ability is required. Herein we validate the use in vitro of
recombinant 6 × His-tagged-PAI-2 lacking the intrahelical loop between C and D alpha-helices (PAI-
2 ΔCD-loop) for these purposes.
Results: We show that PAI-2 ΔCD-loop expressed and purified from the pQE9 vector system
presents an easier purification target than the previously used pET15b system. Additionally, PAI-2
ΔCD-loop gave both higher yield and purity than wild-type PAI-2 expressed and purified under
identical conditions. Importantly, absence of the CD-loop had no impact on the inhibition of both
solution phase and cell surface uPA or on the clearance of receptor bound uPA from the cell
surface. Furthermore, uPA:PAI-2 ΔCD-loop complexes had similar binding kinetics (KD ~5 nM)
with the endocytosis receptor Very Low Density Lipoprotein Receptor (VLDLR) to that previously
published for uPA:PAI-2 complexes.
Conclusion: We demonstrate that the CD-loop is redundant for the purposes of cellular uPA
inhibition and cell surface clearance (endocytosis) and is thus suitable for the development of anti-
uPA targeted cancer therapeutics.
Background
Plasminogen activator inhibitor type-2 (PAI-2) is a clade
B serine protease inhibitor (SERPIN) that is found as both
a 60 kDa glycoprotein and a non-glycosylated 47 kDa
form [1]. Both forms efficiently inhibit soluble or recep-
tor-bound urokinase plasminogen activator (uPA) [1,2]
by the classical serpin inhibitory mechanism resulting in
irreversible inhibition of the enzyme [3]. The majority of
expressed PAI-2 is not secreted and this may be linked to
an inefficient, mildly hydrophobic internal signal peptide
[4,5]. Thus, whilst PAI-2 levels in plasma are normally too
low to be detected, in conditions such as pregnancy, some
myelomonocytic leukemias and in inflammatory tissue,
PAI-2 is consistently detected in plasma and other body
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fluids as both a glycoprotein and in the 47 kDa form [5-
9]. This suggests a role for PAI-2 in extracellular protease
inhibition in vivo.
We have previously shown that exogenous PAI-2 effi-
ciently inhibits cell surface uPA receptor (uPAR)-bound
uPA leading to the rapid clearance of the inhibited com-
plex from the cell surface via receptor mediated endocyto-
sis [2]. This involves interactions with endocytosis
receptors of the Low Density Lipoprotein receptor (LDLR)
family leading to delivery of uPAR/uPA/PAI-2 to endo-
somes and lysosomes [2,10,11]. Tumour overexpression
of uPA/uPAR and the related uPA inhibitor PAI-1
(SERPINE1) strongly correlates to metastatic potential
[12-16] and poor patient prognosis [17-20], but the pres-
ence of PAI-2 is associated with benign tumours and
increased, relapse-free survival [9]. As such, we proposed
that the ability of PAI-2 to remove cell surface uPA and
hence proteolytic activity, without activation of the pro-
mitogenic/motogenic signalling pathways associated with
PAI-1 [9,11], accounts for the differential prognosis seen
for PAI-2 versus PAI-1 [9-11].
Therefore, the ability of PAI-2 to specifically target uPA
and hence tumour cells without interacting with compo-
nents of the ECM or modifying other cellular behaviours
that may promote tumour cell behaviour (unlike PAI-1)
[11], supports the use of exogenous PAI-2 as the basis of
uPA targeted cancer treatments. Promising results using
SDS-PAGE analysis of highly enriched recombinant PAI-2  proteins Figure 1
SDS-PAGE analysis of highly enriched recombinant 
PAI-2 proteins. 10 μg of total protein from PAI-2 ΔCD-
loop purified from either pET15b (lane 1) or pQE9 (lane 2), 
or wild-type PAI-2 from pQE9 (lane 3) were fractionated by 
a 10% SDS-PAGE under reducing conditions. The slight dif-
ference in size between PAI-2 ΔCD-loop from pET15b and 
pQE9 is due to differences in tag/linker length. * marks 
cleaved PAI-2 in wild-type population as mentioned in text.
Quantitative analysis of the purification of PAI-2 ΔCD-loop from pQE9 Figure 2
Quantitative analysis of the purification of PAI-2 ΔCD-loop from pQE9. Protein (100 μL) was injected onto a cation 
exchange column and eluted using a linear NaCl gradient (0–1 M) at 1 mL/min. PAI-2 ΔCD-loop was detected at 280 nm with 
a RT of 42.606 min. Integration of the peak corresponding to PAI-2 ΔCD-loop measured the purity at 94.5%. The green line 
indicates the relative amount of buffer B (MES pH 5.0, 1 M NaCl) to buffer A (MES pH 5.0). Insert: Relative retention times 
hatand purity as calculated from AUC using Empower Pro V2 (Waters) software. RT = retention time.BMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
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bismuth-213 labelled PAI-2 have been obtained in a
number of in vitro,  in vivo and preclinical evaluations
which show clear cell targeting specificity and tumour effi-
cacy with minimal side effects in relevant animal models
[21-27]. These studies used full length wild-type PAI-2,
but it may be possible to utilise smaller, more easily pro-
ducible PAI-2 constructs. This would require validation in
terms of its extracellular uPA inhibitory and clearance
functions.
Previous studies have reported the purification of PAI-2
from placenta [28], cultured human monocytes [29],
transfected CHO cells [30,31], baculovirus infected insect
larvae [32], yeast [33] and Escherichia coli [30,34-43].
Methods of PAI-2 expression in E. coli have generally uti-
lised a one or two step purification procedure, usually
involving metal affinity chromatography and/or ion
exchange chromatography. The shift in the literature
towards affinity tag based systems for the production of
recombinant PAI-2 constructs [34-39] allows for the puri-
fication of PAI-2 under milder, native conditions and
avoidance of denaturation/renaturation [35] or extreme
pH treatment [30] as used previously. The presence of an
N-terminal 6 × His-tag has previously been shown to have
no significant impact on the uPA inhibitory activity of
PAI-2 [36]. Generally, His-tags are believed to have no
effect on overall protein structure [44].
An issue associated with the purification of recombinant
wild-type PAI-2 is that PAI-2 contains a 33 amino acid int-
rahelical loop between alpha helices C and D (known as
the CD-loop) which is accessible for cleavage in both E.
coli or mammalian expression systems [34]. This results in
two fractions of recombinant PAI-2 which retain inhibi-
tory activity but require additional purification steps such
as ion-exchange chromatography [34]. Di Giusto et al.
[38] showed that 6 × His-tagged PAI-2 lacking the CD-
loop (termed PAI-2 ΔCD-loop) can be purified with a
one-step procedure and exhibited identical soluble phase
uPA inhibitory activity.
The functionality of the CD-loop has been described pri-
marily in an intracellular context and remains somewhat
controversial [9]. The CD-loop is involved in transglutam-
inase mediated cross-linking to cellular and ECM proteins
[43,45], although the functional significance of this cross-
linking is unknown. Interestingly, cross-linked PAI-2
maintains uPA inhibitory activity. The CD-loop is
believed to be highly mobile [34] and as such the crystal
structure of PAI-2 has only been resolved for a CD-loop
deletion mutant [42].
Altogether, this suggests that PAI-2 ΔCD-loop, being easy
to produce and purify in addition to retaining uPA inhib-
itory activity, could be used as an exogenous uPA targeting
substitute for wild-type PAI-2 in a therapeutic setting. To
this end, we compared the expression and purification of
6 × His-tagged wild type PAI-2 and PAI-2 ΔCD-loop and
show for the first time that the cell bound uPA inhibitory
activity and rapid clearance of uPAR/uPA by PAI-2 is not
compromised by the 6 × His-tagged form lacking the CD-
loop.
A positive ion ESI-MS of PAI-2 ΔCD-loop from pQE9 in 10 mM ammonium acetate (pH 6.8) containing 0.1% formic acid Figure 3
A positive ion ESI-MS of PAI-2 ΔCD-loop from pQE9 in 10 mM ammonium acetate (pH 6.8) containing 0.1% 
formic acid. The m/z spectrum shows a Gaussian-type distribution of multiply charged ions ranging from m/z 2700 – 4500. 
Charge states are indicated. The monomeric (A) and dimeric (B) forms of the protein gave a measured molecular mass of 
44496 Da (± 0.89) and 88961 Da (± 0.84), respectively. Mass was calculated using MassLynx MS software (Waters) and cae-
sium iodide was used for external calibration.BMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
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Results and discussion
Expression and purification of PAI-2 ΔCD-loop
Expression and purification of PAI-2 ΔCD-loop from both
the pET15b and pQE9 vector systems yielded a product
migrating as a major band at 45 kDa (Figure 1). This cor-
responds to the expected molecular weight of PAI-2 ΔCD-
loop and was confirmed via western blotting with a mon-
oclonal antibody to PAI-2 (data not shown). The PAI-2
ΔCD-loop from the pQE9 system contained fewer impu-
rities (seen as lower molecular weight bands; Figure 1)
compared to PAI-2 ΔCD-loop from pET15b expressed and
purified under similar conditions (Figure 1, compare
lanes 1 and 2). The abundance of PAI-2 ΔCD-loop
expressed and purified from the pQE9 versus the pET15b
system was found to be ~95% pure compared to ~74%,
respectively, as measured by densitometry. The purity of
PAI-2 ΔCD-loop was confirmed via HPLC, with integra-
tion of the elution profile giving PAI-2 ΔCD-loop an
abundance of ~95% (Figure 2). The expression and puri-
fication of PAI-2 ΔCD-loop using the pQE9 system regu-
larly achieved yields between 10 and 15 mg/L of culture.
Wild-type PAI-2 expressed and purified using the pQE9
system was less pure (Figure 1, compare lanes 1 and 3)
and of lower yield (~5 mg/L) compared to PAI-2 ΔCD-
PAI-2 ΔCD-loop efficiently inhibits both solution phase and cell bound uPA activity Figure 4
PAI-2 ΔCD-loop efficiently inhibits both solution phase and cell bound uPA activity. A. PAI-2 ΔCD-loop is able to 
form SDS stable complexes with uPA. PAI-2 ΔCD-loop was incubated in a 2:1 molar ratio with HMW-uPA for 30 min and ana-
lysed by a 10% SDS-PAGE under reducing conditions. B. Immunoblot analysis of complex formation between uPA and PAI-2 
ΔCD-loop using a monoclonal antibody to the A-chain of uPA (~30 kDa), indicating that no residual uPA remains in the sample. 
C. Kinetic inhibition curves for wild-type PAI-2 (dark red) versus PAI-2 ΔCD-loop (bright pink) against HMW-uPA in solution. 
The uPA fluorogenic substrate was briefly pre-incubated with the PAI-2 forms or buffer alone (open circles) and the assays ini-
tiated by the addition of HMW-uPA. Fluorescence units were converted to a percentage of the maximal (uninhibited) uPA 
activity. Values shown are the means of triplicate determinations. Errors (<10%) are not shown for clarity of presentation. D. 
U937 cells were incubated with uPA fluorogenic substrate in the absence or presence of wild-type PAI-2 (filled bars) or PAI-2 
ΔCD-loop (open bars) for 1 h at 37°C. Fluorescence units were converted to a percentage of the maximal (uninhibited) uPA 
activity. Values shown are means ± SEM (n = 3). *p < 0.001 compared to inhibited samples for both PAI-2 forms.BMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
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loop. When visualised by SDS-PAGE under reducing con-
ditions, wild-type PAI-2 yielded two bands that were iden-
tified as PAI-2 via western blotting (data not shown). This
confirms our previous observation that a portion of wild-
type PAI-2 is cleaved in the CD-loop [34], which would
require further purification steps to obtain a homogenous
protein population.
Electrospray Ionisation Mass Spectrometry (ESI-MS)
The mass spectrometry data presented here is the first
spectrum of any PAI-2 construct to be published. The ESI-
MS spectrum of PAI-2 ΔCD-loop (Figure 3) shows a pat-
tern of multiply charged ions (13+ to 16+) in the m/z range
of 2700–3500 consistent for the 45 kDa monomeric spe-
cies. The calculated molecular weight of 44496.72 Da is in
agreement with the theoretical monoisotopic molecular
weight of 44480.16 Da. In addition, five higher charge
states (20+ to 24+) from m/z 3,700 – 4,500 representing an
89 kDa dimeric species were also observed. Lobov et al.
[34] showed that whilst less polymergenic than wild-type
PAI-2, PAI-2 ΔCD-loop was still able to form dimers and
higher order aggregates.
The absence of the CD-loop does not affect the solution 
phase or cell surface uPA activity inhibitory function of 
PAI-2
To ensure that the PAI-2 ΔCD-loop construct generated in
this study retained uPA inhibitory activity, excess PAI-2
ΔCD-loop was incubated with uPA and analysed by SDS-
PAGE under reducing conditions (Figure 4A). A band at
~95 kDa was observed corresponding to covalently com-
plexed uPA:PAI-2 ΔCD-loop. Additionally, western blot-
ting of this complex formation using a monoclonal
antibody to uPA showed no free uPA remained after incu-
bation (Figure 4B). PAI-2 ΔCD-loop and wild-type PAI-2
gave super-imposable kinetic inhibition curves for HMW-
uPA in solution (Figure 4C), confirming that the absence
of the CD-loop does not affect uPA inhibitory activity of
PAI-2. Di Giusto et al. [38] showed that His-tagged PAI-2
ΔCD-loop had the same second order rate constant (2.40
× 106M-1 s-1) as the published wild-type non-recombinant
form. Moreover, we show that the inhibitory activity of
both variants was also identical towards cell surface recep-
tor bound uPA as there were no significant differences
seen between the two PAI-2 forms (Figure 4D). This indi-
cates that the absence of the CD-loop is also redundant in
the more physiological setting of the cell surface. This is to
be expected as the majority of serpin sequence deviation
occurs in the loops joining secondary structures [46].
Moreover, the intrahelical CD-loop is a unique feature of
clade B serpins [47] which is absent (and hence not
Cellular internalisation of uPA is equivalent between wild- type PAI-2 and PAI-2 ΔCD-loop as determined by flow  cytometry Figure 5
Cellular internalisation of uPA is equivalent between 
wild-type PAI-2 and PAI-2 ΔCD-loop as determined 
by flow cytometry. MCF-7 cells were incubated with 10 
nM uPA:Alexa488, either alone or in complex with wild-type 
PAI-2 or PAI-2 ΔCD-loop for 1 h at 37°C. Any surface bound 
uPA:Alexa488 remaining was quenched by incubation with 4 
μg/mL anti-Alexa488 polyclonal antibody for 30 min prior to 
analysis by dual colour flow cytometry. Values shown are 
means ± SEM (n = 3) as a percentage of uPA only treat-
ment.*p < 0.005 compared to internalisation in the absence 
of RAP for each treatment.
*
*
*
Table 1: Kinetic parameters of the interaction between PAI-2 ΔCD-loop or wild-type PAI-2 and VLDLR, both alone and in complex 
with uPA.
Analyte Binding Model ka
(M-1 s-1)
kd
(s-1)
KD
(nM)
χ2
PAI-2 wild-type No binding - - - -
uPA:PAI-2 wild-type 1:1 3.75 × 105
(± 1.1 × 105)
1.44 × 10-3
(± 0.39 × 10-3)
4.81
(± 0.64)
4.71
PAI-2 ΔCD-loop No binding - - - -
uPA:PAI-2 ΔCD-loop 1:1 4.16 × 105
(± 1.8 × 105)
1.36 × 10-3
(± 0.23 × 10-3)
4.34
(± 0.56)
3.28
Values were determined using surface plasmon resonance. Binding data was fitted using the BIAevaluation 4.0 software. The binding model chosen 
represents that with the lowest χ2 value. (Values are the average ± SEM, n = 3).BMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
Page 6 of 9
(page number not for citation purposes)
required for function) in inhibitory serpins of all other
clades.
Removal of the CD-loop does not affect the clearance of 
uPA from the cell surface
Preliminary dot-blot analysis suggested that removal of
the CD-loop of PAI-2 has no impact on the interaction
between uPA complexed PAI-2 and members of the LDLR
family [10]. Surface plasmon resonance was used to meas-
ure the affinity of uPA complexed with PAI-2 ΔCD-loop or
wild-type PAI-2 for the endocytosis receptor VLDLR. The
KD of both uPA:PAI-2 ΔCD-loop and uPA:wild-type PAI-2
for VLDLR was found to be ~5 nM (Table 1) and these
interaction best fit a 1:1 binding model. Additionally, no
interaction was observed between VLDLR and either PAI-
2 ΔCD-loop or wild-type PAI-2 alone (Table 1). These
findings are in agreement with those of Croucher et al.
[11], which was determined using non-tagged, wild-type
PAI-2. Additionally, when complexed with uPA, both
wild-type PAI-2 and PAI-2 ΔCD-loop lead to an almost
two-fold increase in the amount of uPA endocytosed by
MCF-7 cells relative those treated with uPA alone (Figure
5). Importantly, there was no significant difference
between cells treated with uPA:wild-type PAI-2 and
uPA:PAI-2  ΔCD-loop. Pre-treatment of cells with the
LDLR antagonist RAP significantly reduced the amount of
uPA internalised in all treatments (Figure 5). This also
confirms the role of VLDLR in endocytosis, as it is the only
LDLR family member of relevance on MCF-7 cells [11].
Conclusion
This study shows that the CD-loop of PAI-2 plays no role
in the inhibition and clearance of cell surface uPA in vitro.
Additionally, we confirm previous findings indicating
that the use of PAI-2 ΔCD-loop is advantageous compared
to wild-type PAI-2 due to superior purity and yield of the
recombinant protein under identical conditions. As such,
PAI-2 ΔCD-loop appears to present a desirable basis for
the development of PAI-2 based uPA targeted cancer ther-
apies. Furthermore, tumour uptake increases as protein
size is decreased [48], suggesting that this shortened but
fully active form of PAI-2 may not only be simpler to
express and purify than wild-type PAI-2, but also exhibit a
favourable pharmacokinetic profile.
Methods
Materials
The expression vectors pET15b/PAI-2 wild-type and
pET15b/PAI-2 ΔCD-loop were a kind gift from Prof. T Ny
(Umea University, Sweden); pQE9 vector and M15
[pREP4] E. coli obtained from QIAgen; Oligonucleotides
from Sigma-Genosys; phorbyl myristate acetate (PMA)
from Sigma-Aldrich; Alexa488 labelling kit, Alexa488 poly-
clonal antibody and BL21 Star (DE3) E. coli from Invitro-
gen; IPTG from Applichem; Monoclonal antibodies
against human uPA (#394) and human PAI-2 (#3750),
and high molecular weight (HMW)-uPA from American
Diagnostica; Ampicillin and kanamycin from Amresco;
TALON metal affinity resin from Clontech; BamHI restric-
tion enzyme, shrimp alkaline phosphatase and T4 DNA
ligase from Fermentas; CM5 BIAcore chip and PD-10
desalting columns from GE BioSciences; Recombinant
VLDLR ligand binding region was a gift from D Blaas
(Medical University of Vienna, Austria); Z-Gly-Gly-Arg-
AMC from Calbiochem; Wild-type PAI-2 from PAI-2 Pty
Ltd; Pfu HS Fusion II DNA polymerase from Stratagene.
Generation of pQE9/PAI-2 constructs
Wild-type PAI-2 and PAI-2 ΔCD-loop cDNAs lacking the
3' untranslated region were amplified from pET15b using
Pfu HS Fusion II DNA polymerase and the following
primers: 5'-GCGCGGATCCCTCGAGGATCTTTGTGT-
GGC-3' (forward) and 5'-GCGCGGATCCTTAGGGTGAG-
GAAAATCTGCCG-3' (reverse). Primers contained BamHI
sites to allow for ligation into pQE9. Both vector and
insert were digested with BamHI, linear pQE9 de-phos-
phorylated using shrimp alkaline phosphatase and the
insert ligated into the vector using T4 DNA ligase. Success-
ful insertion and sequence integrity were confirmed using
restriction digestion and DNA sequencing.
Expression and purification of PAI-2
Purified pET15b/PAI-2 ΔCD-loop, pQE9/PAI-2 ΔCD-loop
and pQE9/PAI-2 wild-type vectors were transformed into
chemically competent BL21 Star (DE3) and M15 [pREP4]
cells, respectively, using standard methods. Cells were cul-
tured overnight at 37°C with shaking in LB containing
100 μg/mL ampicillin and 25 μg/mL kanamycin (only for
M15 [pREP4] cells). A 20 mL aliquot of this starter culture
was added to 1 L Z-broth (LB with the addition of 1 g/L
glucose and 0.49 g/L CaCl2.2H2O) and grown to an
OD600  of ~0.6. Expression of PAI-2 ΔCD-loop was
induced by the addition of 0.5 mM IPTG and the culture
incubated for a further 4 h. Cells were collected by centrif-
ugation at 10,000 g for 10 min. Pelleted cells were resus-
pended in 15 mL of ice-cold loading buffer (50 mM
NaH2PO4, 300 mM NaCl, pH 7.0, containing 5 mM imi-
dazole for pET15b expressed PAI-2 ΔCD-loop) and lysed
using a French press (Thermo, USA). The cell lysate (~20
mL) was then incubated with 2.5 μg of DNase for 30 min
on ice and cell debris pelleted by centrifugation at 17,000
g for 30 min. The supernatant was loaded onto equili-
brated TALON metal affinity resin at a rate of 1 mL/min.
Unbound proteins were removed using 10 column vol-
umes of loading buffer followed by 10 column volumes of
wash buffer containing optimised imidazole concentra-
tions (data not shown) (50 mM NaH2PO4, 300 mM NaCl,
5 mM imidazole for pQE9, 15 mM for pET15b, pH 7.0).
Bound protein was eluted from the column using elution
buffer (50 mM NaH2PO4, 300 mM NaCl, 150 mM imida-BMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
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zole, pH 7.0). Purification was analysed using SDS-PAGE
under reducing conditions and the successful isolation of
PAI-2 ΔCD-loop determined by western blotting using a
monoclonal antibody against PAI-2. Samples were buffer
exchanged into phosphate buffer (50 mM NaH2PO4, 300
mM NaCl, pH 7.0) to remove imidazole for subsequent
experiments.
Cation-exchange high performance liquid 
chromatography (HPLC)
The purity of PAI-2 ΔCD-loop expressed and purified
from pQE9 was further determined by ion exchange chro-
matography on a BioSuite SP 10 μm, C × C (7.5 cm × 75
mm) cation exchange semi-preperative column (Waters,
UK). The column was pre-equilibrated with approxi-
mately 10 column volumes of 20 mM 2-(N-mor-
pholino)ethanesulfonic acid (MES, pH 5.0). PAI-2 ΔCD-
loop (100 μL, ~1 mg/mL) was then loaded and eluted
with a linear (curve 6) 0.5 M NaCl salt gradient at 1 mL/
min. The data was collected on a photodiode array (PDA)
at 280 nm and percent purity determined using Empower
Pro V2 (Waters, UK) software.
Electrospray ionisation mass spectrometry (ESI-MS)
A positive ion mass spectrum of PAI-2 ΔCD-loop
expressed and purified from pQE9 was acquired on a
quadrupole time of flight spectrometer (Q-TOF-MS)
(Micromass Q-TOF Ultima, Waters, UK) fitted with a Z-
spray ionisation source. A sample of freshly prepared pro-
tein in PBS pH 7.4 was exchanged into 10 mM ammo-
nium acetate buffer (pH 6.8) containing 0.1% formic acid
and made up to a final concentration of 10 μM. The pro-
tein was then injected into the Q-TOF Ultima mass spec-
trometer (20 μL) and the mass spectrum acquired with a
capillary voltage of 2.6 kV, cone voltage of 50 V, source
block temperature of 40°C, and a resolution power of
5000 Hz. Ceasium iodide was used for external calibra-
tion. The mass spectrum data is presented as raw data, on
an m/z scale. Mass was calculated using MassLynx MS soft-
ware (Waters).
Fluorogenic uPA activity assay
Several substrate and uPA concentrations were used to
find the optimum range and to set the gain on a Fluorostar
Optima fluorescence plate reader (BMG Labtech, Ger-
many). PAI-2 ΔCD-loop or wild-type PAI-2 were diluted
in reaction buffer (20 mM Hepes, pH 7.6, 100 mM NaCl,
0.5 mM EDTA, 0.01% (v/v) Tween 20) and mixed with
fluorogenic substrate, Z-Gly-Gly-Arg-AMC in 180 μL reac-
tion buffer. After a brief preincubation at 37°C, HMW-
uPA (final concentration 0.675 nM) was added to start the
reaction and fluorescence emission measured immedi-
ately at 37°C. All assays were performed in triplicate and
values corrected by subtracting the background (reaction
buffer plus substrate only). For cell based assays, PMA
treated U937 cells (used to enhance the expression of
unoccupied uPAR [49]) were washed and preincubated
with 50 nM HMW-uPA in binding buffer (Phenol red free
Hanks buffered salt solution, pH 7.4, containing 1 mM
CaCl2, 1 mM MgCl2 and 0.1% BSA) for 10 min to saturate
uPAR. After 2 washes the cells were resuspended in bind-
ing buffer to give a final concentration of 5 × 105 cells/mL.
To initiate the reaction 100 μL aliquots of the cell suspen-
sion were transferred to a 96-well fluor plate containing
100 μL of 0.5 mM substrate +/- PAI-2 in binding buffer
pre-equilibrated to 37°C (final concentrations, 0.25 mM
substrate, 12.5 or 50 nM PAI-2) and fluorescence emis-
sion measured. All assays were performed in triplicate and
values corrected by subtracting background fluorescence
[binding buffer plus substrate +/- PAI-2 (the presence of
PAI-2 made no difference to background levels)]. Differ-
ences in uPA activity were tested for significance using an
unpaired Student's t-test.
Surface plasmon resonance
Surface plasmon resonance was used to determine the
impact of the removal of the CD-loop and presence of the
6 × His-tag on the affinity of uPA:PAI-2 complexes for
VLDLR, essentially as described by Croucher et al. [11].
VLDLR was immobilised on a CM5 BIAcore chip, accord-
ing to the manufacture's instructions. Briefly, the chip was
activated with a 1:1 mixture of 0.2 M N-ethyl-N'-(3-
dimethylaminopropyl)carbodi-imide and 0.05 M N-
hydroxysuccimide. VLDLR was coated onto the chip at 40
μg/mL in 10 mM sodium acetate (pH 3) to a level of
~2,000 response units. Unoccupied binding sites were
blocked using 1 M ethanolamine, pH 8.5. Ligands were
diluted into running buffer (10 mM Hepes, pH 7.4, 150
mM NaCl, 1 mM CaCl2, 0.005% Tween-20) before appli-
cation to the BIAcore chip at 20 μL/min. Regeneration was
achieved using 100 mM H3PO4. Data was analysed using
BIAevaluation software (Version 4), using a blank cell as
the reference cell.
Internalisation assays
Internalisation assays were conducted essentially as previ-
ously described [2,10,11], using the MCF-7 cell line.
Briefly, cells were grown for 48 h in 6 well plates to sub-
confluency, washed with phenol red free hanks buffered
salt solution (pH 7.4, containing 1 mM CaCl2, 1 mM
MgCl2 and 0.1% BSA), then incubated in binding buffer
for 1 h at 37°C to allow for receptor recycling. To confirm
LDLR specificity, cells were preincubated for 10 min with
200 nM RAP (receptor associated protein). Cells were
incubated with 10 nM uPA:Alexa488, both alone and pre-
viously complexed with either wild-type PAI-2 or PAI-2
ΔCD-loop for 1 h at 37°C to allow for internalisation.
After this incubation period, the cells were washed twice
with ice cold binding buffer, harvested using 5 mM EDTA,
washed again and resuspended in ice cold binding bufferBMC Biotechnology 2009, 9:43 http://www.biomedcentral.com/1472-6750/9/43
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containing 4 μg/mL Alexa488 quenching polyclonal anti-
body. After 30 min the cells were washed twice with ice-
cold PBS and analysed by dual colour flow cytometry with
propidium iodide to exclude non-viable cells as previ-
ously described [2]. Differences in the amount of uPA
internalised between treatments were tested for signifi-
cance using the unpaired Student's t-test.
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